CRP and myocardial infarction: The CANTOS trial, a double-blind, randomized, placebo-controlled outcomes trial involving 10,061 patients with myocardial infarction and inflammatory atherosclerosis characterized by high-sensitivity CRP levels ≥ 2 mg/l, demonstrated a 15% reduction in the risk of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death compared to placebo [60].